

Contents

1 Stem Cell Tourism Phenomenon in China: An Introduction	1
1.1 Reasons for Stem Cell Tourism Phenomenon	1
1.1.1 Values of Human Embryonic Stem Cell (HESC) Research	1
1.1.2 Inconsistency HESC Related Regulations Across Jurisdictions Leads to Stem Cell Tourism in China	3
1.1.3 TRIPS Agreement Cannot Assure Symmetrical Coherence Between Moral Provision Within Patent Law and Moral Provision Outside Patent Law	6
1.1.4 Inadequate Regulation of HESC Research in China	7
1.2 Purpose and Focus of the Book	7
1.3 Conceptual Framework	11
1.4 The Framework of the Book	17
2 The Legal Framework of Stem Cell Science and Medicine in China: An Overview	19
2.1 HESC Research Environment in China	20
2.1.1 HESC Research Funding in China	21
2.1.2 HESC Industry in China	22
2.2 The Legal Framework of HESC Research in China	23
2.2.1 The Patent Law of China and Its Guideline for Patent Examination	24
2.2.2 The Ethical Guideline for HESC Research	25
2.3 Case Studies	27
2.3.1 Whether Article 5 of the Patent Law Excludes Inventions Related to HESC?	27
2.3.2 Whether Adult Stem Cell Has the Practical Applicability Under Article 22 of Patent Law?	31
2.4 Conclusion	33

3	The Moral Dilemma of Stem Cell Science and Medicine	35
3.1	Overview of Moral Issues on HESC Research.	36
3.1.1	Human Dignity and the Rights of Human Embryo	38
3.1.2	Create Embryos for Research	39
3.1.3	Moral Issues in Embryo Donation	40
3.2	The Moral Status of Human Embryo	41
3.2.1	Human Embryos Are Individual Human Beings	41
3.2.2	Human Embryos Are Human Beings, but They Are not Human Persons.	45
3.2.3	Human Embryos Are not Human Beings	48
3.3	What Is the Moral Source of Human Embryos: Use the Discard Human Embryos or Create Human Embryos for Research?.	51
3.3.1	Use the Spare Human Embryos from IVF	51
3.3.2	Create Human Embryos for Research	54
3.4	Will Therapeutic Cloning Use Lead to Reproductive Cloning Use?	56
3.4.1	Will Therapeutic Cloning Use Turn to Commercial Use?	56
3.4.2	Will the Distinction Between Therapeutic Cloning Use and Reproductive Cloning Use Be Impossible to Police?.	58
3.5	Whether Adult Stem Cell Could Be Fully Used as an Alternate to Embryonic Stem Cell?	59
3.5.1	Adult Stem Cell Can Be Fully Used as an Alternate to Embryonic Stem Cell.	60
3.5.2	Adult Stem Cell Cannot Be Fully Used as Alternate Embryonic Stem Cell.	60
3.6	Conclusion	61
4	Stem Cells, Patents and Regulation in China: Inadequacy	63
4.1	The Critical Issues of First Administration Measure on Clinical Stem Cell Research 2015	64
4.1.1	Clarifying the Qualifications of Institution Conducting Clinical Stem Cell Research	65
4.1.2	Establishing the Initial Review, Record Filing Mechanism, and the Research Project Reporting System	66
4.1.3	Reporting the Unsafe Event in Clinical Stem Cell Research	66
4.2	The First Administrative Measure Cannot Effectively Control Stem Cell Therapy in China	67
4.2.1	Lacking Liability Clause	67
4.2.2	Lacking Traceability System.	68
4.2.3	Lacking Expert Responsible Authorities.	69
4.2.4	Non-applicable to Military Hospital.	69

4.3	Can Stem Cell Therapy Be Used in Patient Before Clinic Testing?	70
4.3.1	From the Bench to Bedside: Stem Cell Therapy Should not Be Used in Patient Before Clinic Trials	70
4.3.2	From the Bedside to the Bench: Stem Cell Therapy Should Be Used in Patient Before Clinic Trials.	71
4.4	Moral Exclusion In or Out Patent Law?	72
4.4.1	Low Moral Status of Human Embryo in Practical Application	73
4.4.2	High Moral Status of the Human Embryo in Patent Law	74
4.4.3	Whether the Moral Exclusion Is Proper in China's Patent Law?	75
4.5	Conclusion	76
5	Stem Cells, Patents and Policy in the US: Inefficiency	77
5.1	The Political Background of HESC Regulation	77
5.2	"First Patent, then Questioned"—The Approach of Patentability of Research Involving HESC Research Under Moral Concerns.	79
5.2.1	"Bayh-Dole Model" in HESC Research-Allow Universities to Patent on Research by Federal Funding	80
5.2.2	Patent on Embryo: The Opening of "Human Embryo Farms".	82
5.2.3	HESC Patents Challenges: From Technical Criterion to Moral Concerns	83
5.2.4	Stem Cell Patent: Impediment or not?	86
5.2.5	The Public's "Right to Know" Right	87
5.3	Political Interventions the Federal Funding Control of HESC Research Under Moral Concerns	88
5.3.1	The National Institutes of Health Revitalization Act: Allow Federal Funding of Research Related to Embryos at the Early Stage	90
5.3.2	Dickey-Wicker Amendment: No Federal Funding on HESC Research Involving Destruction Embryo	91
5.3.3	NIH Guideline 2000	93
5.3.4	The Bush Compromise: Accepted the Narrow Explanation of Dickey-Wicker Amendment but Exercised the Executive Power Instead of Legal Power to Allocate Funding.	94
5.3.5	The Report from President Council on Bioethics Clarified that the Enforcement Law Was Dickey Amendment	95
5.3.6	Executive Order by President Obama: Reverse the Bush Policy	96

5.3.7	The Result of Battle Over the Dickey-Wicker Amendment: The Funding Policy of HESC Research by Obama Administration Could Go Ahead	98
5.4	Conflict Between Federal Law and State Law	99
5.4.1	Proposition 71 in California: Success or Failure?	100
5.4.2	Other States	106
5.4.3	The Interstate Alliance on Stem Cell Research (IASCR): A Venue for the States to Cooperate	106
5.4.4	Conflicts Between the Federal and State Regulation.	107
5.5	Conclusion	108
6	Stem Cells, Patents and Morality in the EU: Inconsistency	111
6.1	The Legal Framework of HESC Research in the EUROPE.	113
6.1.1	Moral Criterion of the European Patent Convention (EPC)	115
6.1.2	The Directive 98/44/EC Excludes “Uses Human Embryos for Industrial or Commercial Purpose” from Patenting	116
6.1.3	The European Group on Ethics in Science and New Technologies (EGE) Supply Authoritative Opinions to Legislation	118
6.2	Cases Studies	120
6.2.1	How to Assess the Morality?	120
6.2.2	Whether HESC Should Be Included in “Human Embryo”? What Is the Scope of “Industrial or Commercial Use”?	125
6.3	Regulatory Approaches of National Jurisdiction in HESC Research in EUROPE	133
6.3.1	Permissive Policy: UK Approach	134
6.3.2	Prohibition Policy: German Approach	139
6.3.3	Intermediate Approach: Netherland Policy	144
6.4	Lessons from EUROPE HESC Regulation Reconciliation.	145
6.4.1	Unitary Substantive Patent Law in the EUROPE: Considerable Freedom Still Given to National Legislations	146
6.4.2	The Biotechnology Directive—A Giant Step Towards Harmonising the European Patent Law on Biotechnology	150
6.4.3	No Uniform Moral Definition and Legal Status of Human Embryo	155
6.4.4	Uniform Concept of Human Embryo and Ban on Patenting Inventions that Involve the Destruction of Human Embryos	157

6.4.5	The Attempt of Infusing Moral Control with the Patent Regulation	159
6.4.6	Space for Flexibility on the Basis of Minimum Standards: Let States Decide Moral Provisions Instead of a Universal Moral Standard Due to Culture Difference	161
6.5	Conclusion	161
7	Proposal for Controlling Stem Cell Science and Medicine in China: Internationalism	163
7.1	The Comparative Analysis of HESC Regulations in the US and the EUROPE	164
7.2	A Better Way to Control HESC Research in China: Regulate Research Itself in a International Regime	166
7.2.1	Moral Exclusion Should not Be Regulated by the Patent Law.	166
7.2.2	China's Regulatory Approach on Stem Cell Research and Transfer: State Legislations is More Appropriate than Guideline.	167
7.2.3	A International Reconciled Regime: Minimum Moral Standard for HESC Research	170
7.2.4	The United Nation (UN) is an Appropriate Platform for International HESC Regulation	172
7.2.5	An Established Framework of Human Rights is the Mainstay of a Reconciled International Policy	173
7.2.6	Establish the Authority to Monitor the Reproductive Treatment and Research.	174
7.3	How Does International Agreement Push China to Regulate and Supervise Stem Cell Therapy?.	175
7.3.1	Controlling the Increased Demands	176
7.3.2	Introducing New Rigorous Regulations	176
7.3.3	Creating a Watch List	176
7.3.4	Setting a Dispute Resolution Process	177
7.4	Conclusion	177
	Bibliography.	179

Regulating Human Embryonic Stem Cell in China
A Comparative Study on Human Embryonic Stem Cell's
Patentability and Morality in US and EU

Jiang, L.

2016, XVIII, 200 p. 2 illus., Hardcover

ISBN: 978-981-10-2100-8